Savitz Ryan 4
4 · Dianthus Therapeutics, Inc. /DE/ · Filed Dec 5, 2025
Insider Transaction Report
Form 4
Savitz Ryan
EVP, CFO & CBO
Transactions
- Exercise/Conversion
Common Stock
2025-12-04$8.44/sh+20,000$168,800→ 20,000 total - Sale
Common Stock
2025-12-04$45.18/sh−20,000$903,600→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-04+20,000→ 84,766 totalExercise: $8.44Exp: 2032-06-06→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.